NCT03518554: A First in Human, Dose Escalation Study of JAB-3068 in Adult Patients With Advanced Solid Tumors

NCT03518554
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Known malignant central nervous system (CNS) disease other than neurologically stable, treated brain metastases
https://ClinicalTrials.gov/show/NCT03518554

Comments are closed.

Up ↑